Diminished epidermal growth factor levels in infants with necrotizing enterocolitis
- PMID: 10693661
- DOI: 10.1016/s0022-3468(00)90005-8
Diminished epidermal growth factor levels in infants with necrotizing enterocolitis
Abstract
Background/purpose: Because epidermal growth factor (EGF) is trophic to the intestinal mucosa, and neonatal necrotizing enterocolitis (NEC) is associated with a disrupted intestinal mucosal barrier, the authors sought to determine whether diminished levels of EGF were present in infants with NEC.
Methods: Saliva, serum, and urine specimens were obtained from infants with NEC during a 3-year period (February 1995 to May 1998). Control patients without NEC were chosen based on similar postnatal age and birthweight. EGF levels were determined by enzyme-linked immunosorbent assay (ELISA). Differences between groups were compared using Mann-Whitney Rank sum test with P less than .05 considered significant. Results are presented as mean values +/-SEM.
Results: Twenty-five infants with NEC were compared with 19 control patients. Birth weight (1,616+/-238 g control v. 1,271+/-124 g NEC) and postnatal age (23+/-6 days control v. 22+/-3 days NEC) were similar. Infants with NEC had significantly lower levels of EGF in both saliva (590+/-80 pg/mL control v. 239+/-41 pg/mL NEC; P<.001) and serum (35+/-8 pg/mL control v. 5.6+/-1.9 pg/mL NEC; P<.001). Urinary EGF was also lower in the NEC group, but was not statistically significant.
Conclusions: Premature infants with NEC have significantly diminished levels of salivary and serum EGF. Reduced levels of this growth factor may distinguish infants at risk for NEC and play a pivotal role in the pathogenesis of the perturbed intestinal mucosal barrier that is central to this condition.
Similar articles
-
Cord blood epidermal growth factor as a possible predictor of necrotizing enterocolitis in very low birth weight infants.J Neonatal Perinatal Med. 2013;6(3):257-62. doi: 10.3233/NPM-1370813. J Neonatal Perinatal Med. 2013. PMID: 24246599
-
Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis.J Pediatr. 2007 Apr;150(4):358-63. doi: 10.1016/j.jpeds.2006.11.059. J Pediatr. 2007. PMID: 17382110
-
Epidermal growth factor reduces hepatic sequelae in experimental necrotizing enterocolitis.Biol Neonate. 2006;89(4):227-35. doi: 10.1159/000090015. Epub 2005 Nov 29. Biol Neonate. 2006. PMID: 16319449
-
Epidermal growth factor and necrotizing enterocolitis.Curr Opin Pediatr. 2012 Apr;24(2):160-4. doi: 10.1097/MOP.0b013e3283504ddb. Curr Opin Pediatr. 2012. PMID: 22227788 Review.
-
Heparin-binding EGF-like growth factor (HB-EGF) and necrotizing enterocolitis.Semin Pediatr Surg. 2005 Aug;14(3):167-74. doi: 10.1053/j.sempedsurg.2005.05.005. Semin Pediatr Surg. 2005. PMID: 16084404 Review.
Cited by
-
Influence of Growth Factors on the Development of Necrotizing Enterocolitis.Clin Perinatol. 2019 Mar;46(1):51-64. doi: 10.1016/j.clp.2018.10.005. Epub 2018 Dec 20. Clin Perinatol. 2019. PMID: 30771819 Free PMC article. Review.
-
Proliferative response in necrotising enterocolitis is insufficient to prevent disease progression.Pediatr Surg Int. 2006 Jan;22(1):50-6. doi: 10.1007/s00383-005-1588-1. Pediatr Surg Int. 2006. PMID: 16283334
-
ErbB receptors and their growth factor ligands in pediatric intestinal inflammation.Pediatr Res. 2014 Jan;75(1-2):127-32. doi: 10.1038/pr.2013.210. Epub 2013 Nov 6. Pediatr Res. 2014. PMID: 24402051 Free PMC article. Review.
-
Necrotizing enterocolitis in newborns: pathogenesis, prevention and management.Drugs. 2008;68(9):1227-38. doi: 10.2165/00003495-200868090-00004. Drugs. 2008. PMID: 18547133 Review.
-
Neonatal Necrotizing Enterocolitis -Inflammation and Intestinal Immaturity.Antiinflamm Antiallergy Agents Med Chem. 2009 Sep;8(3):248-259. doi: 10.2174/187152309789152020. Antiinflamm Antiallergy Agents Med Chem. 2009. PMID: 20498729 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources